FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen

July 20, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news